Kenneth Greathouse

This profile gathers the share dealings of Kenneth Greathouse in Zosano Pharma Corp, where the filings describe the role as chief executive. Over a trading history stretching from 14 November 2017 to 23 November 2021, the count stands at 9 filings.

Market trades split into 5 purchases (€105k) and 1 sale (€5,353). Purchases outweigh sales by €99k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 3 share grants. 2021 to date brings no purchases and 1 sale.

Half of the purchases are above €24k and half below. None of the 5 purchases we analysed coincided with buying by another insider of the same company within 30 days.

On 24 November 2021 came the latest disclosure, an open-market sale for €5,353 in Zosano Pharma Corp. The most recent open-market purchase was published on 8 December 2017, 3,241 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.